Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lymphoma Biology and Survival / Applied Tumor Genomics / University of Helsinki

ABSTRACT: Data Access Committee EGAC00001002849

PROVIDER: EGAC00001002849 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Tumor Genomics Research, University of Helsinki

Project description:Organisation EGAO00000001278

| EGAO00000001278 | EGA

University of Helsinki Systems Biology and Turku University Hospital Data Access Committee

Project description:Data Access Committee EGAC00001001978

| EGAC00001001978 | EGA

University of Helsinki Systems Biology and Turku University Hospital Data Access Committee

Project description:Data Access Committee EGAC00001001937

| EGAC00001001937 | EGA

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.

Project description:Extranodal NK/T-cell lymphoma, nasal type (ENKTL), is an aggressive malignancy with a poor prognosis. While the introduction of L-asparaginase in the treatment of this disease has significantly improved the prognosis, the outcome of patients relapsing after asparaginase-based chemotherapy, which occurs in up to 50% of patients with disseminated disease, remains dismal. There is hence an urgent need for effective targeted therapy especially in the relapsed/refractory setting. Gene expression profiling studies have provided new perspectives on the molecular biology, ontogeny and classification of ENKTL and further identified dysregulated signaling pathways such as Janus associated kinase (/Signal Transducer and activation of transcription (JAK/STAT), Platelet derived growth factor (PDGF), Aurora Kinase and NF-?B, which are under evaluation as therapeutic targets. Copy number analyses have highlighted potential tumor suppressor genes such as PR Domain Zinc Finger Protein 1 (PRDM1) and protein tyrosine phosphatase kappa (PTPRK) while next generation sequencing studies have identified recurrently mutated genes in pro-survival and anti-apoptotic pathways. The discovery of epigenetic dysregulation and aberrant microRNA activity has broadened our understanding of the biology of ENKTL. Importantly, immunotherapy via Programmed Cell Death -1 (PD-1) and Programmed Cell Death Ligand1 (PD-L1) checkpoint signaling inhibition is emerging as an attractive therapeutic strategy in ENKTL. Herein, we present an overview of the molecular biology and genomic landscape of ENKTL with a focus on the most promising translational opportunities.

| S-EPMC6073933 | biostudies-literature

Laboratory of Applied Cancer Genomics team

Project description:Data Access Committee EGAC00001002520

| EGAC00001002520 | EGA

Laboratory of Applied Cancer Genomics team

Project description:Data Access Committee EGAC00001002554

| EGAC00001002554 | EGA

Laboratory of Applied Cancer Genomics team

Project description:Data Access Committee EGAC00001002541

| EGAC00001002541 | EGA

Laboratory of Applied Cancer Genomics team

Project description:Data Access Committee EGAC00001002580